Skip to content

ImPACT Version 4-Touchscreen: Normative and Reliability Study

ImPACT Version 4-Touchscreen: Normative and Reliability Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05551520
Enrollment
1437
Registered
2022-09-22
Start date
2022-02-07
Completion date
2024-10-01
Last updated
2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Concussion

Keywords

Brain

Brief summary

This research study is designed to establish normative database and reliability of ImPACT for adolescents and adults ages 12 through 80 to expand the use of devices to include touchscreen.

Detailed description

This research study is designed to establish normative database and reliability of ImPACT for adolescents and adults ages 12 through 80 to expand the use of devices to include touchscreen. Enrollment will be 900 participants.

Interventions

DEVICENormative

ImPACT will be administered at baseline testing

DEVICEReliability

ImPACT will be administered again within 60 days of baseline test

Sponsors

ImPACT Applications, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age 12-80 2. Primary English speaking or fluent in English

Exclusion criteria

1. Documentation of a known special education diagnosis other than a 504 designation. 2. History of concussion less than 6 months to the study participation 3. Known physical (e.g., visual impairment not fixable by usual means, such as glasses) or psychological impairment (ADHD, LDD, etc.) that would affect their ability to perform the test.

Design outcomes

Primary

MeasureTime frameDescription
Validity12 monthsImPACT Touchscreen performs within normal parameters of ImPACT Online

Secondary

MeasureTime frameDescription
ReliabilityBaseline test will be administered at enrollment and re-test will be administered within 60 days of baseline test.Reliability will be established through a test/re-test. ImPACT Touchscreen will be administered at 2 time points to establish results should be stable over time.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026